220 related articles for article (PubMed ID: 24098749)
1. Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET.
Lin KJ; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Hsiao IT
PLoS One; 2013; 8(9):e75952. PubMed ID: 24098749
[TBL] [Abstract][Full Text] [Related]
2. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
Hsiao IT; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Lin KJ
JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
[TBL] [Abstract][Full Text] [Related]
4. Deuterated
Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF
Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients.
Hsiao IT; Weng YH; Lin WY; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lu CS; Lin KJ
Nucl Med Biol; 2014 Apr; 41(4):322-9. PubMed ID: 24503330
[TBL] [Abstract][Full Text] [Related]
6. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
Weng CC; Chen ZA; Chao KT; Ee TW; Lin KJ; Chan MH; Hsiao IT; Yen TC; Kung MP; Hsu CH; Wey SP
PLoS One; 2017; 12(3):e0173503. PubMed ID: 28257461
[TBL] [Abstract][Full Text] [Related]
8. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
[TBL] [Abstract][Full Text] [Related]
9. An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [
Zhao C; Liu C; Tang J; Xu Y; Xie M; Chen Z
Mol Imaging Biol; 2020 Apr; 22(2):265-273. PubMed ID: 31165386
[TBL] [Abstract][Full Text] [Related]
10. Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
Ma JH; Dong C; Qiao HW; Barret O; Tamagnan GD; Mao W; Xu EH; Zhang C; Lu J; Chan P; Liu SY
Mov Disord; 2024 May; 39(5):847-854. PubMed ID: 38477228
[TBL] [Abstract][Full Text] [Related]
11. Quantitative study of
Jung Lung H; Weng YH; Wen MC; Hsiao IT; Lin KJ
Sci Rep; 2018 Oct; 8(1):16027. PubMed ID: 30375444
[TBL] [Abstract][Full Text] [Related]
12. PET Imaging of Vesicular Monoamine Transporter 2 in Early Diabetic Retinopathy Using [
Li J; Chen P; Bao Y; Sun Y; He J; Liu X
Mol Imaging Biol; 2020 Oct; 22(5):1161-1169. PubMed ID: 31650482
[TBL] [Abstract][Full Text] [Related]
13. MicroPET imaging of vesicular monoamine transporter 2 revealed the potentiation of (+)-dihydrotetrabenazine on MPTP-induced degeneration of dopaminergic neurons.
Xu Y; Tang J; Liu C; Zhao C; Cao S; Yu H; Chen Z; Xie M
Nucl Med Biol; 2021; 96-97():9-18. PubMed ID: 33647803
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [
Naganawa M; Lim K; Nabulsi NB; Lin SF; Labaree D; Ropchan J; Herold KC; Huang Y; Harris P; Ichise M; Cline GW; Carson RE
Mol Imaging Biol; 2018 Oct; 20(5):835-845. PubMed ID: 29468404
[TBL] [Abstract][Full Text] [Related]
15. PET Imaging of VMAT2 with the Novel Radioligand [
Nag S; Jahan M; Tóth M; Nakao R; Varrone A; Halldin C
ACS Chem Neurosci; 2021 Dec; 12(24):4580-4586. PubMed ID: 34813272
[TBL] [Abstract][Full Text] [Related]
16. PET imaging with [
Tang J; Xu Y; Liu C; Fang Y; Cao S; Zhao C; Huang H; Zou M; Chen Z
Nucl Med Biol; 2020; 90-91():1-9. PubMed ID: 32861175
[TBL] [Abstract][Full Text] [Related]
17. [
Weng CC; Huang SL; Chen ZA; Lin KJ; Hsiao IT; Yen TC; Kung MP; Wey SP; Hsu CH
Ann Nucl Med; 2017 Aug; 31(7):506-513. PubMed ID: 28451991
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of
Naganawa M; Lin SF; Lim K; Labaree D; Ropchan J; Harris P; Huang Y; Ichise M; Carson RE; Cline GW
Nucl Med Biol; 2016 Dec; 43(12):743-751. PubMed ID: 27673755
[TBL] [Abstract][Full Text] [Related]
19. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
[TBL] [Abstract][Full Text] [Related]
20. Effects of anesthetics on vesicular monoamine transporter type 2 binding to ¹⁸F-FP-(+)-DTBZ: a biodistribution study in rat brain.
Chen Z; Tang J; Liu C; Li X; Huang H; Xu X; Yu H
Nucl Med Biol; 2016 Jan; 43(1):124-129. PubMed ID: 26526872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
